ALKS - Alkermes plc

NasdaqGS - NasdaqGS Delayed price. Currency in USD
50.56
-0.53 (-1.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close51.09
Open51.20
Bid0.00 x 0
Ask0.00 x 0
Day's range50.23 - 51.37
52-week range42.75 - 63.40
Volume600,587
Avg. volume698,713
Market cap7.77B
Beta2.31
PE ratio (TTM)-39.29
EPS (TTM)-1.29
Earnings date31 Oct 2017 - 6 Nov 2017
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target est62.00
Trade prices are not sourced from all markets
  • Business Wire9 hours ago

    Alkermes to Host Conference Call to Discuss Third Quarter 2017 Financial Results

    Alkermes plc will host a conference call and webcast presentation at 8:30 a.m. ET on Thursday, Oct. 26, 2017, to discuss the company’s third quarter 2017 financial results.

  • Business Wire9 hours ago

    Alkermes to Host Conference Call to Discuss Third Quarter 2017 Financial Results

    DUBLIN--(BUSINESSWIRE)-- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Oct. 26, 2017, to discuss the company’s third quarter ...

  • Business Wire2 days ago

    New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry

    Results from the first-ever study directly comparing the effectiveness of once-monthly extended-release naltrexone (VIVITROL®) to daily buprenorphine-naloxone in patients with opioid dependence were published this week in the Journal of the American Medical Association (JAMA) Psychiatry. VIVITROL is Alkermes’ (NASDAQ: ALKS) once-monthly, non-narcotic medication for the prevention of relapse to opioid dependence, following opioid detoxification. In the 12-week, open-label, randomized-controlled study, 159 patients with opioid dependence were randomized to treatment with either extended-release naltrexone or buprenorphine-naloxone, following detoxification.

  • Business Wire2 days ago

    New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry

    Results from the first-ever study directly comparing the effectiveness of once-monthly extended-release naltrexone to daily buprenorphine-naloxone in patients with opioid dependence were published this week in the Journal of the American Medical Association Psychiatry.

  • Business Wire4 days ago

    Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting

    Alkermes plc today announced that two posters on ALKS 8700, a novel, oral monomethyl fumarate prodrug candidate in development for the treatment of relapsing forms of multiple sclerosis , will be presented at MSParis2017, the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and the Americas Committee for Treatment and Research in Multiple Sclerosis , being ...

  • Business Wire4 days ago

    Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting

    Alkermes plc (NASDAQ: ALKS) today announced that two posters on ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms of multiple sclerosis (MS), will be presented at MSParis2017, the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), being held Oct. 25-28, 2017 in Paris, France. Interim safety and gastrointestinal (GI) tolerability data during the first three months of treatment with ALKS 8700 from the ongoing two-year, open-label, phase 3 safety study will be presented. A poster detailing the study design for the ongoing phase 3 GI tolerability study comparing ALKS 8700 to TECFIDERA® will also be presented.

  • Barrons.com16 days ago

    [$$] 6 Top Pharma Picks for Q4

    Credit Suisse In the final quarter of 2017, we anticipate investors will continue to keep an eye on macro issues such as U.S. drug pricing and potential U.S. corporate tax reform, although a significant amount of product news should also impact how investors view the various names. Overall, we believe sentiment on the group remains relatively robust with noise on the drug pricing side far below what it has been and investors still cautiously optimistic on the possibility of corporate tax reform coming through in 2018. Depending on how these issues play out, it could also lead to increased excitement around potential business development and mergers and acquisitions (M&A) in the sector, as we believe most of our large cap companies are still waiting for further clarity on these issues before announcing transformative deals.

  • Business Wire21 days ago

    Alkermes Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis

    Alkermes plc (NASDAQ: ALKS) participated in the Third Meeting of the President’s Commission on Combating Drug Addiction and the Opioid Crisis held yesterday in Washington, D.C. The Commission was formed to study the scope and effectiveness of the Federal response to drug addiction and the opioid crisis and to make recommendations to the President for improving that response. Alkermes CEO Richard Pops joined government, nonprofit, and business organizations at yesterday’s meeting to testify in support of the Commission’s ongoing effort to discuss innovative solutions to address the opioid crisis.

  • Business Wirelast month

    Patients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA®

    Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 4 clinical study of ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Data from the open-label prospective study showed that switching to treatment with ARISTADA led to statistically significant and clinically meaningful improvement in schizophrenia symptoms at the end of the six-month study in patients who had experienced inadequate response or intolerance to INVEGA SUSTENNA® (paliperidone palmitate). “These data further add to the substantial body of evidence supporting the differentiated efficacy and safety profile of ARISTADA in the treatment of this chronic and debilitating disease,” said Elliot Ehrich, M.D., Executive Vice President, Research and Development of Alkermes.

  • Business Wirelast month

    Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

    Alkermes plc (NASDAQ: ALKS) today announced that the company is now accepting applications for the 2nd annual ALKERMES INSPIRATION GRANTS® initiative. The competitive program will award up to $1 million in grants to organizations for implementation of innovative, high-impact and replicable programs designed to make a positive difference in the lives of people affected by mental health and substance use disorders.

  • Business Wirelast month

    Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

    DUBLIN--(BUSINESSWIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that its Chief Financial Officer, James Frates, will participate in a fireside chat at the Morgan Stanley 15 th Annual Global Healthcare ...

  • Business Wirelast month

    Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress

    DUBLIN--(BUSINESSWIRE)-- — Poster Presentations to Highlight Company’s Broad Research Commitment to Schizophrenia, Opioid Dependence and Depression — — First Presentation of Recently Completed Phase 4 ...

  • Business Wire2 months ago

    Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder

    Alkermes plc (NASDAQ:ALKS) today announced the initiation of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), seeking marketing approval of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action, for the adjunctive treatment of major depressive disorder (MDD). The company expects to complete the submission of the NDA for this Fast Track designated medicine by year-end 2017.

  • Business Wire3 months ago

    Alkermes plc Reports Second Quarter 2017 Financial Results

    DUBLIN--(BUSINESSWIRE)-- — Second Quarter Revenues Increased 12% Year-Over-Year to $218.8 Million, GAAP Loss per Share of $0.28 and Non-GAAP Earnings per Share of $0.01 — — Net Sales of Proprietary Commercial ...

  • Business Wire3 months ago

    Alkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results

    DUBLIN--(BUSINESSWIRE)-- Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, July 27, 2017, to discuss the company’s second quarter 2017 financial results. ...

  • Business Wire4 months ago

    Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder

    Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The study will evaluate the efficacy and safety of ALKS 5461 in patients suffering from MDD who have had an inadequate response to commonly prescribed drugs for depression, including selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).

  • Business Wire4 months ago

    Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference

    DUBLIN--(BUSINESSWIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 38 th Annual Global Healthcare ...

  • Business Wire4 months ago

    Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients

    Alkermes plc (NASDAQ: ALKS) today announced the initiation of ENLIGHTEN-Early, a supportive study in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia. ENLIGHTEN-Early will evaluate the weight gain profile of ALKS 3831 over a 12-week treatment period compared to olanzapine, an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities including significant weight gain, in young adult patients with schizophrenia, schizophreniform or bipolar I disorder who are early in their illness.

  • Business Wire4 months ago

    FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia

    Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is now FDA-approved in four doses and three dosing duration options (441 mg, 662 mg or 882 mg once monthly, 882 mg once every six weeks and 1064 mg once every two months) and can be initiated at any dose or interval, offering an unprecedented range of flexibility to patients and healthcare providers. “We designed ARISTADA to offer flexibility to meet the real-world needs of patients suffering from schizophrenia and the healthcare professionals providing their care.

  • Business Wire5 months ago

    Alkermes’ Corporate Presentation to Be Webcast at the Jefferies Healthcare Conference

    DUBLIN--(BUSINESSWIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies Healthcare Conference on Tuesday, June 6, 2017 at 1:30 p.m. ET ...

  • Business Wire5 months ago

    Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs

    Alkermes plc (NASDAQ: ALKS) today announced the appointment of Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs. Dr. Hopkinson will be responsible for the advancement and implementation of the clinical development programs for Alkermes’ pipeline of drug candidates.

  • Business Wire5 months ago

    Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting

    Alkermes plc (NASDAQ: ALKS) today announced that data from FORWARD-5 and pooled data from FORWARD-4 and FORWARD-5, two phase 3 studies of ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD), will be presented at the Society of Biological Psychiatry (SOBP) Annual Meeting in San Diego, Calif. Management will also host a webcast presentation on May 18, 2017 to discuss the data. ALKS 5461 is a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of MDD in patients who have an inadequate response to standard therapies for clinical depression.

  • Business Wire6 months ago

    Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia

    Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in ENLIGHTEN-1, the first of two key phase 3 studies in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. The multinational, randomized, double-blind phase 3 study is designed to evaluate the antipsychotic efficacy of ALKS 3831 compared to placebo over four weeks in patients experiencing an acute exacerbation of schizophrenia. The study also includes a comparator arm of olanzapine, an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain.

  • Business Wire6 months ago

    Alkermes plc Reports First Quarter 2017 Financial Results

    DUBLIN--(BUSINESSWIRE)-- — First Quarter Revenues Increased 22% Year-Over-Year to $191.8 Million, GAAP Loss per Share of $0.45 and Non-GAAP Loss per Share of $0.18 — — VIVITROL ® Net Sales Grew by 33% ...

  • Business Wire6 months ago

    Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care Conference

    DUBLIN--(BUSINESSWIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 42 nd Annual Health Care Conference on Wednesday, May 3, 2017 ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes